<DOC>
	<DOCNO>NCT00920855</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability bendamustine combination therapy bortezomib patient relapsed/refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Study Bendamustine Combined With Bortezomib Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>The patient : diagnosis multiple myeloma . currently multiple myeloma measurable disease . must receive least 1 previous treatment regimen show sign progressive disease time study entry . woman child bear potential ( surgically sterile least 12 month naturally postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study . man , must agree use acceptable method contraception throughout study 90 day last dose study drug . must Eastern Cooperative Oncology Group ( ECOG ) performance status great 2. must lifeexpectancy great 3 month . must meet specific protocolrelated hematological laboratory criterion within 14 day enrollment . The patient : prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) . plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ( POEMS ) syndrome . plasma cell leukemia . nonmeasurable multiple myeloma . Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 ( great ) peripheral neuropathy within 14 day enrollment . previously participate Cephalonsponsored clinical study bendamustine . impaired cardiac function clinically significant cardiac disease . undergone major surgery within 4 week prior screen recover side effect therapy . severe hypercalcemia . concurrent severe and/or uncontrolled medical psychiatric condition . know positivity human immunodeficiency virus ( HIV ) hepatitis B C. history allergic reaction attributable compound similar chemical biological composition bendamustine , bortezomib , boron , mannitol . receive chemotherapy within 3 week enrollment , exception nitrosoureas , discontinue least 6 week enrollment . receive corticosteroid ( great 10 mg/day prednisone equivalent ) within 3 week enrollment . receive immunotherapy , antibody , radiation therapy within 4 week enrollment . status pregnant lactate woman . Any woman become pregnant study withdrawn study . status male whose sexual partner woman childbearing potential use effective birth control . use investigational drug within 1 month screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>